Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
作者信息
Sun Fangfang, Lin Yanwei, Wang Xiaodong, Gao Yuan, Ye Shuang
机构信息
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201114, China.
Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
出版信息
Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14.
Abstract
摘要
相似文献
1
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.用于免疫功能低下且因感染新型冠状病毒而住院的患者的帕罗韦德。
Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14.
2
Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.新冠病毒感染的移植受者使用帕罗韦德治疗的特殊注意事项
Am J Kidney Dis. 2022 Apr;79(4):480-482. doi: 10.1053/j.ajkd.2022.01.001. Epub 2022 Jan 12.
3
Three more points about Paxlovid for covid-19.关于用于治疗新冠的帕罗韦德（Paxlovid），还有三点要讲。
BMJ. 2022 Jun 7;377:o1397. doi: 10.1136/bmj.o1397.
4
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.辉瑞公司研发的新冠病毒治疗药物 Paxlovid 对公共卫生的影响，美国。
Emerg Infect Dis. 2024 Feb;30(2):262-269. doi: 10.3201/eid3002.230835. Epub 2024 Jan 5.
5
African clinical trial denied access to key COVID drug Paxlovid.非洲一项临床试验被拒绝获取关键新冠药物帕罗韦德。
Nature. 2022 Apr;604(7906):412-413. doi: 10.1038/d41586-022-00919-5.
6
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
7
Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department.在资源有限的急诊科中使用帕罗韦德治疗2019冠状病毒病患者的经验
Ann Emerg Med. 2022 Oct;80(4):382-383. doi: 10.1016/j.annemergmed.2022.05.029.
8
New Data on Paxlovid Reported.新的帕克洛维德数据报告。
Am J Nurs. 2022 Oct 1;122(10):59. doi: 10.1097/01.NAJ.0000890244.62778.a4.
9
A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.一项关于帕罗韦德治疗严重急性呼吸综合征冠状病毒 2 感染血液透析患者的初步研究。
Front Med. 2024 Feb;18(1):169-179. doi: 10.1007/s11684-023-1011-0. Epub 2023 Nov 18.
10
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.帕克洛维德药物说明书中列出的相互作用，根据风险、药物类别和后果进行分类。
Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13.
引用本文的文献
1
Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study.COVID-19免疫功能低下住院患者的临床结局及高炎症反应的影响：一项回顾性队列研究
J Inflamm Res. 2025 Mar 7;18:3385-3397. doi: 10.2147/JIR.S482940. eCollection 2025.
2
A comprehensive immune repertoire signature distinguishes pulmonary infiltration in SARS-CoV-2 Omicron variant infection.一种全面的免疫组库特征可区分新冠病毒奥密克戎变异株感染中的肺部浸润情况。
Front Immunol. 2024 Dec 17;15:1486352. doi: 10.3389/fimmu.2024.1486352. eCollection 2024.
3
In vitro study on efficacy of SKF7, a Malaysian medicinal plant product against SARS-CoV-2.马来西亚药用植物产品 SKF7 抗 SARS-CoV-2 的体外研究。
BMC Complement Med Ther. 2024 Sep 11;24(1):333. doi: 10.1186/s12906-024-04628-6.
4
Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study.COVID-19 肺炎肾移植受者的临床特征和结局：一项单中心回顾性队列研究。
Front Cell Infect Microbiol. 2024 Aug 15;14:1392491. doi: 10.3389/fcimb.2024.1392491. eCollection 2024.
5
Clinical feature of omicron infection in children with inborn errors of immunity in China.中国先天性免疫缺陷患儿感染奥密克戎的临床特征。
Front Immunol. 2024 Jul 23;15:1420547. doi: 10.3389/fimmu.2024.1420547. eCollection 2024.
6
Oral antivirals for COVID-19 among patients with cancer.癌症患者的 COVID-19 口服抗病毒药物。
Support Care Cancer. 2024 Jul 9;32(8):496. doi: 10.1007/s00520-024-08714-w.
7
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments.一位 67 岁男性，患有慢性淋巴细胞白血病（CLL），正在接受伊布替尼维持治疗，伴有持续性 SARS-CoV-2 感染，对抗病毒治疗无反应。
Am J Case Rep. 2024 Jun 29;25:e941165. doi: 10.12659/AJCR.941165.
8
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity.保护弱势群体：满足免疫功能受损人群的 COVID-19 护理需求。
Front Immunol. 2024 May 2;15:1397040. doi: 10.3389/fimmu.2024.1397040. eCollection 2024.
9
Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor.PAXLOVID在血液系统肿瘤COVID-19患者中的临床特征和药代动力学
Med Rev (2021). 2024 Mar 4;4(2):169-171. doi: 10.1515/mr-2023-0068. eCollection 2024 Apr.
10
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.解读历史故事：2019冠状病毒病对血液系统恶性肿瘤患者的影响——2020年至2022年EPICOVIDEHA研究见解
EClinicalMedicine. 2024 Mar 18;71:102553. doi: 10.1016/j.eclinm.2024.102553. eCollection 2024 May.
本文引用的文献
1
Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic.上海针对当前新冠疫情奥密克戎毒株浪潮所做出的拯救生命的努力。
Lancet. 2022 May 28;399(10340):2011-2012. doi: 10.1016/S0140-6736(22)00838-8. Epub 2022 May 6.
2
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
3
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients.免疫功能低下患者中的 COVID-19：癌症、造血细胞和实体器官移植患者的系统评价。
J Infect. 2021 Mar;82(3):329-338. doi: 10.1016/j.jinf.2021.01.022. Epub 2021 Feb 4.
4
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
Zotero 插件